Abstract：From the perspective of failed technological innovation project,retrospecting the rescue process of four failed innovative drugs,such as thalidomide,this paper analyzes the behaviors and roles of all scientists,extractes the “core scientists”who played a key role in the rescue process,and then summarizes its two characteristics of “crossover type”and “highly heterogeneous integration capability”.Such scientists are typical Pasteur quadrant scientists.Finally,it provides some useful management enlightenment for scientists coping with innovation failure and effectively rescuing failed technological innovation in the field of biopharmaceuticals and other fields in China.
[1]李天柱,马佳,刘小琴.挖掘研发失败项目的价值——提高生物制药研发柔性的思路及启示[J].科学学研究,2013,31 (8):1165-1170. [2]MARX V.May data are your data[J].Nature biotechnology,2012,30 (6):509-511. [3]NAPPER A D,MUCKE H A M.A special focus on drug repurposing,rescue,and repositioning[J].Assay and drug development technologies,2015,13 (6):57-72. [4]BOGUSKI M S,MANDL K D,SUKHATME V P.Repurposing with a difference[J].Science,2009,324 (5933):1394-1395. [5]CHESBROUGH H.Business model innovation:opportunities and barriers[J].Long range planning,2010,43 (2-3):354-363. [6]李天柱,侯锡林,马佳.技术创新成功与失败的纯理论思考[J].技术经济与管理研究,2016 (3):24-28. [7]李天柱,王倩,侯锡林.再定位式创新[J].科学学与科学技术管理,2018,39 (3):136-143. [8]白东鲁,沈竞康.新药研发案例研究——明星药物如何从实验室走向市场[M].北京:化学工业出版社,2017. [9]巴伯.科学与社会秩序[M].北京:三联书店出版社,1991. [10]EISENHARDT K M.Building theories from case study research[J].Academy of mandgement review,1989 (14):532-550. [11]YIN R.Case study research:design and methods[M].2nd ed.Beverly Hills,CA:Sage Publishing,1994. [12]PETTIGREW A M.Longitudinal field research on change:theory and practice[J].Organization science,1990,3 (1):267-292. [13]CHAKRAVARTHY B S,DOZ Y L.Strategy process research[J].Strategic management journal,1992 (13):5-14. [14]刘丽华,杨乃定.针对案例研究局限性的案例研究方法操作过程设计[J].科学管理研究,2005,23 (6):118-221. [15]EISENHARDT K M,GRAEBNER M E.Theory building from cases:opportunities and challenges[J].Academy of management journal,2007,50 (1):25-32. [16]苏敬勤,崔淼.工商管理案例研究方法[M].北京:科学出版社,2011. [17]李天柱,银路,石忠国.生物制药创新中的专家型公司和核心公司研究——兼论中国生物制药区域产业创新平台建设[J].中国软科学,2011 (11):108-116. [18]李天柱,银路,程跃.美国生物制药企业的发展路径研究及其启示[J].中国软科学,2010 (5):136-142,181. [19]ORSENIGO L.The emergence of biotechnology:institutions and markets in industrial innovation[M].New York:St Martin′s Press,1989. [20]李天柱,银路,程跃.现代生物技术研发柔性研究[J].科学学研究,2010,28 (2):189-194. [21]DAY G S,SCHOEMAKER P J H,GUNTHER R E.Wharton on managing emerging technologies[M].New York:John Wiley&Sons Canada,Limited,2000:245-247. [22]李天柱,马佳,梁萌萌,等.接力创新的一般规律及应用价值——以生物制药产业为例[J].技术经济,2012,31 (11):9-14. [23]STOKES E D.Pasteur′s quadrant:basic science and technological innovation[M].Washington:Brookings Institution Press,1997. [24]司托克斯 D E.基础科学与技术创新:巴斯德象限[M].周春彦等,译.北京:科学出版社,1999. [25]周程,张杰军.跨越创新过程中的 “死亡之谷”——科技成果产业化问题刍议[J].科学学与科学技术管理,2010(3):50-55.
2020, 
